ArticleLife (Basel, Switzerland)2025
Subjective Olfactory Impairment in a Patient Undergoing Anti-Obesity Pharmacotherapy: A Case of Symptom-Test Discrepancy.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the growing use of anti-obesity medications (AOMs), particularly glucagon-like peptide-1 (GLP-1) receptor agonists, interest in their impact on chemosensory function has increased. We report a case of subjective olfactory discomfort that developed during AOM therapy despite normal objective test results. A 41-year-old woman received the GLP-1 receptor agonist semaglutide for 24 weeks. Thorough olfactory function evaluation was performed using the Questionnaire of Olfactory Disorders (a validated questionnaire), the Yonsei Olfactory Function Test (for psychophysical testing), and chemical gustometry. The tests were performed before treatment and after 24 weeks of AOM therapy. At baseline, the patient had no olfactory complaints and showed normal test results. After treatment, she reported significant subjective olfactory discomfort (visual analog scale score: 48, maximum: 50), with decreased quality of life and parosmia, despite stable Yonsei Olfactory Function scores and normal gustatory function. This case highlights the possible mismatch between subjective and objective olfactory assessment during AOM therapy. Comprehensive chemosensory evaluations and interdisciplinary collaboration are essential, and further large-scale long-term studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.